for people ages 18 years and up (full criteria)
study started
completion around
Principal Investigator
by Aaron Logan, MD, PhD (ucsf)
Headshot of Aaron Logan
Aaron Logan



Prospective determination of the clinical utility of measurable residual disease (MRD) testing for relapse and survival of patients with acute myeloid leukemia (AML) undergoing allogeneic hematopoietic cell transplantation (alloHCT).


This is a multi-center non-randomized prospective study designed to establish a national framework for introducing measurable residual disease testing into the clinical care of AML patients undergoing allogeneic transplantation.

Enrollment is expected to occur over a 4-year period, with an additional 3 years of follow-up. Subject participation this study will be approximately 3 years. Up to 1,000 subjects will be enrolled.

Subjects will be asked to provide blood samples at months 1-6, 9, 12, 15, and 18 post-transplant, and archived specimens from time of AML diagnosis and any bone marrow samples collected for clinical purposes will be requested for research testing. Additional blood and marrow samples will be requested at relapse (if applicable).


Acute Myeloid Leukemia in Remission, Prospective determination of the clinical utility of measurable residual disease (MRD) testing


You can join if…

Open to people ages 18 years and up

  1. Provision of signed and dated informed consent form
  2. Stated willingness to comply with all study procedures and availability for the duration of the study
  3. Aged at least 18 years old at time of consent
  4. Diagnosed with AML, in complete remission
    1. Complete remission (CR) definition per local institutional criteria
    2. CR with incomplete hematologic recovery (CRi) is not an exclusion criterion
    3. MRD positivity is not an exclusion criterion
  5. Undergoing alloHCT
  6. Has specimen from time of AML diagnosis available

You CAN'T join if...

  1. Diagnosis of acute promyelocytic leukemia
  2. Prior alloHCT


  • University of California, San Francisco accepting new patients
    San Francisco California 94143 United States
  • City of Hope accepting new patients
    Duarte California 91010 United States
  • Stanford University accepting new patients
    Stanford California 94305 United States

Lead Scientist at University of California Health

  • Aaron Logan, MD, PhD (ucsf)
    Dr. Aaron Logan is a Professor of Clinical Medicine at the University of California, San Francisco (UCSF). His clinical practice focuses on the management of patients with acute leukemias, myelodysplastic syndrome, aplastic anemia and hemophagocytic lymphohistiocytosis. Dr. Logan also runs a research laboratory and is director of the Hematologic Malignancies Tissue Bank at UCSF.


accepting new patients
Start Date
Completion Date
Center for International Blood and Marrow Transplant Research
Study Type
Expecting 1000 study participants
Last Updated